Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

David Scott Miller, John A. Blessing, Jeanne Schilder, Adnan Munkarah, Yi Chun Lee

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objectives. To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus. Topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Twenty-seven member institutions entered 51 patients. Of the patients entered, 48 were eligible. Patient characteristics included a median age of 65, with 33% having prior radiation and 92% having prior chemotherapy. Twenty-six patients (54%) had a performance status (PS) of 0, 18 (38%) had a PS of 1, and four (8%) had a PS of 2. Patients received from 1 to 21 (with a median of 2) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 35 (73%) patients, leukopenia in 14 (29%), and thrombocytopenia in 10 (21%). Three (6%) patients developed neutropenic sepsis and died shortly after their first treatment cycle. There were five (10%) complete responses; 13 (27%) patients maintained stable disease, 26 (54%) experienced increasing disease, and reassessment did not occur in four (8%). Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalGynecologic Oncology
Volume98
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Topotecan
Carcinosarcoma
Uterus
Malignant Mixed Tumor
Drug Therapy
Leukopenia
Neutropenia
Thrombocytopenia
Disease Progression
Sepsis
Appointments and Schedules

Keywords

  • Camptothecin
  • Carcinosarcoma
  • Topoisomerase-1 inhibition
  • Topotecan
  • Uterine neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II evaluation of topotecan in carcinosarcoma of the uterus : A Gynecologic Oncology Group study. / Miller, David Scott; Blessing, John A.; Schilder, Jeanne; Munkarah, Adnan; Lee, Yi Chun.

In: Gynecologic Oncology, Vol. 98, No. 2, 08.2005, p. 217-221.

Research output: Contribution to journalArticle

Miller, David Scott ; Blessing, John A. ; Schilder, Jeanne ; Munkarah, Adnan ; Lee, Yi Chun. / Phase II evaluation of topotecan in carcinosarcoma of the uterus : A Gynecologic Oncology Group study. In: Gynecologic Oncology. 2005 ; Vol. 98, No. 2. pp. 217-221.
@article{9005b2c08470488e9260f955b8b5d358,
title = "Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study",
abstract = "Objectives. To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus. Topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Twenty-seven member institutions entered 51 patients. Of the patients entered, 48 were eligible. Patient characteristics included a median age of 65, with 33{\%} having prior radiation and 92{\%} having prior chemotherapy. Twenty-six patients (54{\%}) had a performance status (PS) of 0, 18 (38{\%}) had a PS of 1, and four (8{\%}) had a PS of 2. Patients received from 1 to 21 (with a median of 2) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 35 (73{\%}) patients, leukopenia in 14 (29{\%}), and thrombocytopenia in 10 (21{\%}). Three (6{\%}) patients developed neutropenic sepsis and died shortly after their first treatment cycle. There were five (10{\%}) complete responses; 13 (27{\%}) patients maintained stable disease, 26 (54{\%}) experienced increasing disease, and reassessment did not occur in four (8{\%}). Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.",
keywords = "Camptothecin, Carcinosarcoma, Topoisomerase-1 inhibition, Topotecan, Uterine neoplasms",
author = "Miller, {David Scott} and Blessing, {John A.} and Jeanne Schilder and Adnan Munkarah and Lee, {Yi Chun}",
year = "2005",
month = "8",
doi = "10.1016/j.ygyno.2005.05.015",
language = "English (US)",
volume = "98",
pages = "217--221",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II evaluation of topotecan in carcinosarcoma of the uterus

T2 - A Gynecologic Oncology Group study

AU - Miller, David Scott

AU - Blessing, John A.

AU - Schilder, Jeanne

AU - Munkarah, Adnan

AU - Lee, Yi Chun

PY - 2005/8

Y1 - 2005/8

N2 - Objectives. To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus. Topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Twenty-seven member institutions entered 51 patients. Of the patients entered, 48 were eligible. Patient characteristics included a median age of 65, with 33% having prior radiation and 92% having prior chemotherapy. Twenty-six patients (54%) had a performance status (PS) of 0, 18 (38%) had a PS of 1, and four (8%) had a PS of 2. Patients received from 1 to 21 (with a median of 2) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 35 (73%) patients, leukopenia in 14 (29%), and thrombocytopenia in 10 (21%). Three (6%) patients developed neutropenic sepsis and died shortly after their first treatment cycle. There were five (10%) complete responses; 13 (27%) patients maintained stable disease, 26 (54%) experienced increasing disease, and reassessment did not occur in four (8%). Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.

AB - Objectives. To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus. Topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Twenty-seven member institutions entered 51 patients. Of the patients entered, 48 were eligible. Patient characteristics included a median age of 65, with 33% having prior radiation and 92% having prior chemotherapy. Twenty-six patients (54%) had a performance status (PS) of 0, 18 (38%) had a PS of 1, and four (8%) had a PS of 2. Patients received from 1 to 21 (with a median of 2) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 35 (73%) patients, leukopenia in 14 (29%), and thrombocytopenia in 10 (21%). Three (6%) patients developed neutropenic sepsis and died shortly after their first treatment cycle. There were five (10%) complete responses; 13 (27%) patients maintained stable disease, 26 (54%) experienced increasing disease, and reassessment did not occur in four (8%). Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.

KW - Camptothecin

KW - Carcinosarcoma

KW - Topoisomerase-1 inhibition

KW - Topotecan

KW - Uterine neoplasms

UR - http://www.scopus.com/inward/record.url?scp=22544451218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544451218&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.05.015

DO - 10.1016/j.ygyno.2005.05.015

M3 - Article

C2 - 15975641

AN - SCOPUS:22544451218

VL - 98

SP - 217

EP - 221

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -